MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-02-2023
ImmunoGen Retained Earnings 2011-2026 | IMGN
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings ImmunoGen
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.69 B | -1.47 B | -1.33 B | -1.29 B | -1.18 B | -1.03 B | -854 M | -709 M | -648 M | -577 M | -504 M | -431 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -431 M | -1.69 B | -977 M |
Quarterly Retained Earnings ImmunoGen
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.71 B | -1.74 B | -1.74 B | -1.69 B | -1.64 B | - | -1.5 B | -1.47 B | -1.43 B | -1.4 B | -1.37 B | -1.33 B | -1.33 B | -1.33 B | -1.33 B | -1.29 B | -1.29 B | -1.29 B | -1.29 B | -1.18 B | -1.18 B | -1.18 B | -1.18 B | -1.03 B | -1.03 B | -1.03 B | -1.03 B | -933 M | -933 M | -933 M | -854 M | -776 M | -743 M | -709 M | -709 M | -657 M | -670 M | -648 M | -648 M | -584 M | -588 M | -577 M | -577 M | -554 M | -529 M | -504 M | -504 M | -463 M | -450 M | -431 M | -431 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -431 M | -1.74 B | -1.01 B |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
667 M | $ 21.66 | 1.14 % | $ 1.01 B |  USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-73.8 M | $ 0.9 | -0.2 % | $ 6.62 M | China |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
-2.2 B | $ 22.33 | 1.66 % | $ 3.7 B | USA |
 |
Esperion Therapeutics
ESPR
|
-1.62 B | $ 1.94 | 1.31 % | $ 403 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Galectin Therapeutics
GALT
|
-433 M | $ 2.38 | 2.33 % | $ 152 M | USA |
 |
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-66.2 M | $ 24.07 | -0.58 % | $ 313 M | USA |
 |
Heron Therapeutics
HRTX
|
-1.94 B | $ 1.18 | -0.84 % | $ 197 M | USA |
 |
ImmuCell Corporation
ICCC
|
-15.2 M | $ 8.26 | -1.07 % | $ 74.6 M | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
InflaRx N.V.
IFRX
|
-168 M | $ 1.61 | 8.78 % | $ 152 M | Germany |
 |
Allakos
ALLK
|
-1.12 B | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-160 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Innate Pharma S.A.
IPHA
|
-220 M | $ 1.39 | 0.72 % | $ 235 M | France |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Inventiva S.A.
IVA
|
-33.6 M | $ 5.11 | -0.78 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
-400 M | $ 0.29 | -25.25 % | $ 676 K | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
-237 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
-469 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-353 M | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-196 M | - | 17.91 % | $ 11.1 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-763 M | $ 19.09 | -2.75 % | $ 1.03 B | Britain |
 |
BioNTech SE
BNTX
|
-410 M | $ 102.36 | -2.94 % | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
-105 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-447 M | $ 4.11 | 0.61 % | $ 439 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-1.14 B | $ 23.18 | -0.34 % | $ 2.95 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
-1.39 B | $ 1.43 | -0.7 % | $ 381 M | Britain |
 |
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
5.3 B | - | - | $ 96.9 B | Britain |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
499 M | $ 240.72 | 4.09 % | $ 4.4 B | USA |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
Eli Lilly and Company
LLY
|
24.5 B | $ 874.81 | -1.06 % | $ 785 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-176 M | $ 2.9 | -0.34 % | $ 4.77 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |